Department of Medical Physiology, School of Medicine, University of Nairobi, P,O, Box 30197-00100, Nairobi, Kenya.
Global Health. 2013 Nov 5;9:55. doi: 10.1186/1744-8603-9-55.
Glycated haemoglobin (HbA1C) measurement is the currently accepted gold standard biochemical indicator of long-term glycemic control in diabetic patients. The level of knowledge as well as the frequency of use of this test among diabetic patients in Kenya is unknown. The current study aimed to document this among patients attending the diabetes clinic at a national referral hospital in Kenya.
One hundred and ninety eight diabetic patients (59 male and 139 female) attending the outpatient diabetes clinic at the Kenyatta National Hospital were interviewed on their level of knowledge and use of the HbA1C test, as well as their last HbA1C level. The respondent answers were tabulated, analyzed and summarized. The sample mean, standard deviation and percentages were calculated.
Of the 198 patients interviewed, 11 (5.6%) had type I diabetes mellitus (DM) while 187 (94.4%) had type II DM. One hundred and thirty four patients (67.7%) had heard of the HbA1C test while 64 patients (32.3%) had never heard of the test. Forty patients (20.2%) had at one point done the test while 158 (79.8%) had never done the test. The mean HbA1C level of the 40 patients who had at any one time done the test was 8.5 ± 1.7%, with more than 90% having HbA1C > 8%.
Using self-reported accounts, the current study indicates inadequate knowledge and infrequent testing of HbA1C among diabetic outpatients in Kenya. This lack of knowledge and awareness may lead to increased susceptibility to the development of diabetic complications, and potentially higher healthcare costs among these patients. It is our recommendation that policy makers focus on strategies that address HbA1C test accessibility in Kenya, including financial coverage by the national insurance to access the test in public facilities, so as to effectively monitor and combat DM.
糖化血红蛋白(HbA1C)测量是目前公认的糖尿病患者长期血糖控制的金标准生化指标。在肯尼亚,糖尿病患者对该检测的了解程度以及使用频率尚不清楚。本研究旨在肯尼亚国立转诊医院的糖尿病门诊患者中记录这一情况。
对在肯雅塔国家医院门诊糖尿病诊所就诊的 198 例糖尿病患者(59 例男性,139 例女性)进行了关于他们对 HbA1C 检测的了解程度和使用情况以及他们最近的 HbA1C 水平的访谈。对受访者的回答进行制表、分析和总结。计算样本均值、标准差和百分比。
在接受采访的 198 例患者中,11 例(5.6%)患有 1 型糖尿病(DM),而 187 例(94.4%)患有 2 型 DM。134 例患者(67.7%)听说过 HbA1C 检测,而 64 例患者(32.3%)从未听说过该检测。40 例患者(20.2%)曾进行过该检测,而 158 例患者(79.8%)从未进行过该检测。曾经进行过检测的 40 例患者的平均 HbA1C 水平为 8.5±1.7%,其中超过 90%的患者 HbA1C>8%。
根据自我报告的情况,本研究表明肯尼亚的糖尿病门诊患者对 HbA1C 的了解不足,检测也不频繁。这种缺乏知识和意识可能导致患者更容易发生糖尿病并发症,并可能导致这些患者的医疗保健费用增加。我们建议政策制定者关注解决肯尼亚 HbA1C 检测可及性的策略,包括国家保险对在公共设施中进行检测的财务覆盖,以有效监测和防治糖尿病。